68Ga-TATE-RGD

68Ga-TATE-RGD (also known as [68Ga]Ga-DOTA-3P-TATE-RGD) is a dual-targeting radiopharmaceutical molecular probe developed by Peking Union Medical College Hospital for positron emission tomography (PET/CT) imaging. It is designed to simultaneously target somatostatin receptor 2 (SSTR2) and integrin αvβ3, both of which are frequently overexpressed in various malignancies. By combining the TATE peptide (a somatostatin analog) and the RGD peptide (an integrin-binding motif) into a single construct labeled with gallium-68, the agent aims to provide more comprehensive tumor characterization and improved diagnostic sensitivity compared to single-target tracers like 68Ga-DOTATATE. It is currently being evaluated in early-phase clinical trials for the detection and staging of neuroendocrine tumors, iodine-resistant thyroid cancer, and meningioma.

Other names

68Ga-labeled DOTA-TATE-RGDTATE-RGD[68Ga]Ga-DOTA-TATE-RGD